AstraZeneca Total Assets 2010-2023 | AZN

AstraZeneca total assets from 2010 to 2023. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • AstraZeneca total assets for the quarter ending December 31, 2023 were $101.119B, a 4.8% increase year-over-year.
  • AstraZeneca total assets for 2023 were $101.119B, a 4.8% increase from 2022.
  • AstraZeneca total assets for 2022 were $96.483B, a 8.43% decline from 2021.
  • AstraZeneca total assets for 2021 were $105.363B, a 57.9% increase from 2020.
AstraZeneca Annual Total Assets
(Millions of US $)
2023 $101,119
2022 $96,483
2021 $105,363
2020 $66,729
2019 $61,377
2018 $60,651
2017 $63,354
2016 $62,526
2015 $60,056
2014 $58,595
2013 $55,899
2012 $53,534
2011 $52,830
2010 $56,127
2009 $54,920
AstraZeneca Quarterly Total Assets
(Millions of US $)
2023-12-31 $101,119
2023-09-30 $96,086
2023-06-30 $96,543
2023-03-31 $96,687
2022-12-31 $96,483
2022-09-30 $94,185
2022-06-30 $96,579
2022-03-31 $100,273
2021-12-31 $105,363
2021-09-30 $107,221
2021-06-30 $73,641
2021-03-31 $64,926
2020-12-31 $66,729
2020-09-30 $64,112
2020-06-30 $59,929
2020-03-31 $57,211
2019-12-31 $61,377
2019-09-30 $58,906
2019-06-30 $61,889
2019-03-31 $61,055
2018-12-31 $60,651
2018-09-30 $61,443
2018-06-30 $61,344
2018-03-31 $63,281
2017-12-31 $63,354
2017-09-30 $64,587
2017-06-30 $65,119
2017-03-31 $60,959
2016-12-31 $62,526
2016-09-30 $63,222
2016-06-30 $64,419
2016-03-31 $64,323
2015-12-31 $60,056
2015-09-30 $54,118
2015-06-30 $55,169
2015-03-31 $53,701
2014-12-31 $58,595
2014-09-30 $56,164
2014-06-30 $58,539
2014-03-31 $59,390
2013-12-31 $55,899
2013-09-30 $54,121
2013-06-30 $53,987
2013-03-31 $52,329
2012-12-31 $53,534
2012-09-30 $52,448
2012-06-30 $51,390
2012-03-31 $50,763
2011-12-31 $52,830
2011-09-30 $52,576
2011-06-30 $53,406
2011-03-31 $54,534
2010-12-31 $56,127
2010-09-30 $56,390
2010-06-30 $54,647
2010-03-31 $54,075
2009-12-31 $54,920
2009-09-30 $51,899
2009-06-30 $50,200
2009-03-31 $46,515
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $204.098B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $731.189B 121.76
Novo Nordisk (NVO) Denmark $553.986B 45.64
Johnson & Johnson (JNJ) United States $389.835B 15.52
Merck (MRK) United States $328.029B 86.30
AbbVie (ABBV) United States $314.591B 16.03
Novartis AG (NVS) Switzerland $220.226B 15.26
Pfizer (PFE) United States $156.744B 15.17
Sanofi (SNY) $123.368B 11.11
Innoviva (INVA) United States $0.992B 8.95